Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 165

    2.

    Re: bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.

    Wood DP.

    J Urol. 2012 Feb;187(2):473-4. Epub 2011 Dec 16. No abstract available.

    PMID:
    22237318
    [PubMed]
    3.

    A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer.

    Zhang X, Shi X, Li J, Hu Z, Zhou D, Gao J, Tan W.

    J Urol. 2012 Mar;187(3):1071-9. Epub 2012 Jan 21.

    PMID:
    22266013
    [PubMed - indexed for MEDLINE]
    4.

    Long-term impact of arsenic in drinking water on bladder cancer health care and mortality rates 20 years after end of exposure.

    Fernández MI, López JF, Vivaldi B, Coz F.

    J Urol. 2012 Mar;187(3):856-61. Epub 2012 Jan 15.

    PMID:
    22248521
    [PubMed - indexed for MEDLINE]
    5.

    Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial.

    Kamat AM, Dickstein RJ, Messetti F, Anderson R, Pretzsch SM, Gonzalez GN, Katz RL, Khanna A, Zaidi T, Wu X, Grossman HB, Dinney CP.

    J Urol. 2012 Mar;187(3):862-7. Epub 2012 Jan 15.

    PMID:
    22245325
    [PubMed - indexed for MEDLINE]
    7.

    Role of CYP1B1 gene polymorphisms in bladder cancer susceptibility.

    Salinas-Sánchez AS, Donate-Moreno MJ, López-Garrido MP, Giménez-Bachs JM, Escribano J.

    J Urol. 2012 Feb;187(2):700-6. Epub 2011 Dec 16.

    PMID:
    22177211
    [PubMed - indexed for MEDLINE]
    8.

    Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer.

    Eswara JR, Efstathiou JA, Heney NM, Paly J, Kaufman DS, McDougal WS, McGovern F, Shipley WU.

    J Urol. 2012 Feb;187(2):463-8. Epub 2011 Dec 15.

    PMID:
    22177159
    [PubMed - indexed for MEDLINE]
    9.

    Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria.

    Herr HW.

    J Urol. 2012 Feb;187(2):435-7. Epub 2011 Dec 15.

    PMID:
    22177154
    [PubMed - indexed for MEDLINE]
    10.

    Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and bacillus Calmette-Guérin immunotherapy for nonmuscle invasive bladder cancer.

    Reis LO, Ferreira U, Billis A, Cagnon VH, Fávaro WJ.

    J Urol. 2012 Feb;187(2):438-45. Epub 2011 Dec 15.

    PMID:
    22177150
    [PubMed - indexed for MEDLINE]
    11.

    Standard lymph node dissection for bladder cancer: significant variability in the number of reported lymph nodes.

    Meijer RP, Nunnink CJ, Wassenaar AE, Bex A, van der Poel HG, van Rhijn BW, Meinhardt W, Horenblas S.

    J Urol. 2012 Feb;187(2):446-50. Epub 2011 Dec 15. Erratum in: J Urol. 2012 Apr;187(4):1513. Meijer, R P P [corrected to Meijer, R P].

    PMID:
    22177147
    [PubMed - indexed for MEDLINE]
    12.

    Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers.

    Shariat SF, Chromecki TF, Cha EK, Karakiewicz PI, Sun M, Fradet Y, Isbarn H, Scherr DS, Bastian PJ, Pummer K, Fajkovic H, Sagalowsky AI, Ashfaq R, Doblinger M, Cote RJ, Lotan Y.

    J Urol. 2012 Feb;187(2):457-62. Epub 2011 Dec 15.

    PMID:
    22177145
    [PubMed - indexed for MEDLINE]
    13.

    Using gene polymorphisms to assess bladder cancer risk: progress and challenges.

    Kiltie AE.

    J Urol. 2012 Feb;187(2):379-80. Epub 2011 Dec 15. No abstract available.

    PMID:
    22177142
    [PubMed - indexed for MEDLINE]
    14.

    Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro.

    Deb AA, Wilson SS, Rove KO, Kumar B, Koul S, Lim DD, Meacham RB, Koul HK.

    J Urol. 2011 Dec;186(6):2426-33. Epub 2011 Oct 21.

    PMID:
    22019171
    [PubMed - indexed for MEDLINE]
    15.

    Clinical reliability of the 2004 WHO histological classification system compared with the 1973 WHO system for Ta primary bladder tumors.

    Pellucchi F, Freschi M, Ibrahim B, Rocchini L, Maccagnano C, Briganti A, Rigatti P, Montorsi F, Colombo R.

    J Urol. 2011 Dec;186(6):2194-9. Epub 2011 Oct 22.

    PMID:
    22019037
    [PubMed - indexed for MEDLINE]
    16.

    Editorial comment.

    Montironi R.

    J Urol. 2011 Dec;186(6):2199-200. Epub 2011 Oct 22. No abstract available.

    PMID:
    22019036
    [PubMed - indexed for MEDLINE]
    17.

    The FGFR3 mutation is related to favorable pT1 bladder cancer.

    van Rhijn BW, van der Kwast TH, Liu L, Fleshner NE, Bostrom PJ, Vis AN, Alkhateeb SS, Bangma CH, Jewett MA, Zwarthoff EC, Zlotta AR, Bapat B.

    J Urol. 2012 Jan;187(1):310-4. Epub 2011 Nov 17.

    PMID:
    22099989
    [PubMed - in process]
    18.

    Influence of renal excretory function on the performance of urine based markers to detect bladder cancer.

    Todenhöfer T, Hennenlotter J, Witstruk M, Gakis G, Aufderklamm S, Kuehs U, Stenzl A, Schwentner C.

    J Urol. 2012 Jan;187(1):68-73. Epub 2011 Nov 16.

    PMID:
    22088333
    [PubMed - in process]
    19.

    Error occurred: cannot get document summary

    PMID:
    21993091

    20.

    Error occurred: cannot get document summary

    PMID:
    21993089

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk